Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Beta Drugs

BETA
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Beta Drugs Share price and Fundamental Analysis

View All Details
View All Details
Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017
Company Incorporation2005
ChairmanRahul Batra
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
1,902.27
PE Ratio
41.54
Industry P/E
31.3
PEG Ratio
0.72
ROE
21.52%
ROCE
19%
ROA
9.72%
Total Debt (Cr)
123.8
Debt to Equity
0.67
Dividend Yield
0%
EPS
45.36
Book Value & P/B
127.83 x 14.74
Face Value
10
Outstanding Shares(Cr)
1.01
Current Ratio
3.41
EV to Sales
5.19

Included In

+More

Stock Returns

1 Week+6.02%
1 Month+4.82%
6 Months-10.44%
1 Year+63.89%
3 Years+125.25%
5 Years+3548.65%

CAGR

1 Year CAGR

Revenue Growth

+30.21%

Net Profit Growth

+18.62%

Operating Profit Growth

+13.87%

Dividend Growth

N/A

Stock Returns CAGR

+66.2%
no_data

No Stocks

Smart Score

2.2
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 66.73%

FIIs : 0.90%

DIIs : 0.00%

Public : 32.36%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Decreased by 0.25% to 0.9% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Beta Drugs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Beta Drugs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017

Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

The company is primarily engaged in the manufacturing of oncology products. The Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. As on March 31, 2017, the company had a portfolio of over 50 products catering to various oncology diseases including breast, brain, bone, lung, mouth, head & neck, prostate, haematology, cervics, oeaophagus etc.

Beta Drugs Share Price

Beta Drugs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Beta Drugs Market Cap

Market capitalization of Beta Drugs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Beta Drugs is valued compared to its competitors.

Beta Drugs PE Ratio

Beta Drugs PE ratio helps investors understand what is the market value of each stock compared to Beta Drugs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Beta Drugs PEG Ratio

The PEG ratio of Beta Drugs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Beta Drugs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Beta Drugs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Beta Drugs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Beta Drugs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Beta Drugs Total Debt

Total debt of Beta Drugs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Beta Drugs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Beta Drugs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Beta Drugs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Beta Drugs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Beta Drugs Technical Analysis

Technical analysis of Beta Drugs helps investors get an insight into when they can enter or exit the stock. Key components of Beta Drugs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Beta Drugs shares often struggle to rise above due to selling pressure.

Beta Drugs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Beta Drugs ’s financial health and profitability.

Beta Drugs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Beta Drugs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Beta Drugs Financials

The financials of Beta Drugs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Beta Drugs Profit and Loss Statements

The profit and loss statement of Beta Drugs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Beta Drugs .

Beta Drugs Balance Sheet

The balance sheet presents a snapshot of Beta Drugs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Beta Drugs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App